

27

28 **1. Introduction**

29 Codeine is an opiate analgesic that is commonly used in a formulation with paracetamol
30 (acetaminophen), although combinations with other analgesics like acetylsalicylic acid,
31 ibuprofen, caffeine, barbiturates and sedative antihistamines may also exist [1]. The drug is
32 often used to suppress a cough either alone or by combining it with other drugs[2]. The major
33 pharmacological effects of codeine such as analgesia, drowsiness, mood changes, respiratory
34 depression, nausea, and decreased gastrointestinal motility are produced on the central
35 nervous system (CNS) and gastrointestinal tract[3].

36 The metabolism of codeine occurs mostly in the liver, and to a lesser extent in the
37 intestine and CNS [1]. Although codeine metabolism resulted in several metabolites, it is
38 morphine, a product of codeine O-demethylation by enzyme cytochrome P450 2D6
39 (CYP2D6), that is responsible for its analgesic effect [4,5]. Codeine dosage is highly
40 regulated, its overdose could cause depressive effects on the central nervous system or death
41 from respiration arrest. The adult minimum lethal oral dose for codeine is estimated to be 0.5–
42 1.0 g, i.e 17–34 pills containing 30 mg codeine [6]. The serum codeine concentrations
43 exceeding 0.3 mg/L have been reported to cause toxicity, while concentrations above 1.6
44 mg/L are considered to be lethal [2].

45 The abuse and misuse of prescription opioids such as codeine have reached an alarming
46 rate in the last ten years. In the United States, it was reported that about 1.2 million visit
47 emergency department (ED) as a result of non-medical use of prescription medications in
48 2011 alone[7]. The production and importation of cough syrup that include codeine as an
49 ingredient was ban by the Nigerian Government in 2018 due to concerns regarding its use by
50 youths to get intoxicated [8]. Many addicts of codeine in many countries are into the habit of
51 using the drug every day without doctor prescriptions which is of great concerns. Therefore,

52 this study assesses the toxic effects of different doses, including overdoses of codeine, on
53 haematological parameters, biochemical changes and oxidative damage in the liver and
54 kidney of rats exposed to normal, high and extreme doses of codeine orally for 28 days.

55

56 **2. Materials and Methods**

57 *2.1. Materials*

58 Centrifuge machine, human automated haematology system analyzer (ERMA PCE
59 210, ERMA, Japan), weighing balance, dissecting sets, cuvette, spectrophotometer, pH meter,
60 refrigerator, homogenizer, razor blade, 1 ml syringes, 2 ml syringes, and 5 ml syringes,
61 surgical gloves, cotton wool, measuring cylinder, test tubes, beaker, spatula, plastic cages,
62 EDTA bottles, plain sample bottles.

63 *2.2. Reagents*

64 Thiobarbituric acid (TBA), nicotinamide adenine dinucleotide reduced (NADH) and
65 Codeine were obtained from Sigma–Aldrich Chemical Co. Ltd. (England).
66 Nitrobluetetrazolium (NBT), 5,5'-Dithiobis (2-nitrobenzoic acid) (DTNB) are the product of
67 Fluka (Buchs, Switzerland). All other chemicals used were analytical grade.

68

69 *2.3. Animals*

70 Twenty (20) male Wistar rats with an average weight of 170-200g were used for the
71 experiments. They were housed in the Ladoke Akintola University of Technology,
72 (LAUTECH) animal house. They were allowed fourteen (14) days to acclimatize before the
73 commencement of drug administration. The animals were maintained on a standard pellet
74 diet throughout the acclimatization and administration period. The animal experimental
75 procedures were conducted in accordance with the National Institutes of Health guide for the

76 care and use of laboratory animals (NIH Publications No. 8023) revised in 2002 and
77 approved by the institutional research committee.

78

79 2.4. *Experimental Design*

80 Twenty(20) male wistar strain albino rats were divided into four groups of five rats each
81 according to their weight. Group I labelled control received saline solution for 28
82 days **through the oral route**. Group II labelled normal codeine received a normal dose of
83 codeine at 5mg/kg/day body weight of rat. Group III labelled high codeine received a high
84 dose of codeine at 25mg/kg/day. Group IV labelled extreme codeine received an extreme
85 dose of codeine at 50mg/kg/day. Codeine was constituted in saline solution and administered
86 through the oral route. During the experiment, the animals were allowed free access to food
87 and distilled water. After 28 days of codeine treatment and after an overnight fast, animals
88 were sacrificed by cardiac puncture under light ether anaesthesia into ethylene diamine tetra-
89 acetic acid (EDTA) sample bottles for haematological analysis and heparinised sample
90 bottles for biochemical analysis. Liver and kidney were removed from the animals for
91 biochemical analyses. Blood samples in heparinized bottles were centrifuged to separate
92 plasma and red blood cells. All samples were stored at -20°C until analysed.

93

94 2.5. *Haematological Study*

95 Freshly collected blood samples in EDTA bottles were analysed for haematological assay
96 using an automatic haematological assay analyser (ERMA PCE 210, ERMA, Japan).
97 Different tested haematological parameters were as follows: White Blood Cell (WBC), Red
98 Blood Cells (RBC), Haemoglobin (HGB), Haematocrit (HCT), Red cells (RDW%), Red cells
99 Distribution Width (**RDW**), Mean Corpuscular Haemoglobin (MCH), Mean Corpuscular

100 Haemoglobin Concentration (MCHC), Platelet (PLT), Mean Platelet Volume (MPV), Mean
101 Corpuscular Volume (MCV), Platelet crit (PCT), Platelet distribution width (PDW).

102

103 *2.6.Determination of Blood Biochemical Parameters*

104 Plasma concentrations of alkaline phosphatase (ALP), aspartate aminotransferase (AST),
105 alanine aminotransferase (ALT), urea, creatinine and total protein were determined using
106 enzymatic kits (CYPRESS® Diagnostics, Langdorp, Belgium) according to the
107 manufacturer's instructions.

108

109 *2.7.Preparation of Liver and Kidney Homogenates*

110 Prior to biochemical analyses, the liver and kidney samples were cut into small pieces and
111 homogenized in Phosphate buffer saline (PBS) with a homogenizer to give a 10 % (w/v) liver
112 and kidney homogenate. The homogenates were then centrifuged at 12,000 rpm for 15 min.
113 The supernatant obtained was used for the assay of superoxide dismutase, catalase, reduced
114 glutathione, thiobarbituric acid reactive substances (TBARS) content, and protein estimation.

115

116 *2.8.Determination of Hepatic and Renal Antioxidant Enzyme Activities and MDA Levels*

117 Hepatic and renal superoxide dismutase (SOD) activities were assayed in the tissue
118 homogenates by the method of Kakkar, *et al.* [9] at 560 nm. One unit of enzyme activity was
119 defined as that amount of enzyme which caused 50% inhibition of nitrobluetetrazolium
120 reduction/mg protein. Catalase (CAT) activity was determined at room temperature by using
121 the method of Aebi[10] and the absorbance of the sample was measured at 240 nm in a UV
122 spectrophotometer. The concentration of reduced glutathione (GSH) in liver and kidney
123 homogenates was measured, as described by Jollow *et al.* [11]. The extent of lipid
124 peroxidation was estimated as the concentration of thiobarbituric acid-reactive product

125 malondialdehyde (MDA), using the method of Draper and Hadley, [12]. All of the enzyme
126 activities were expressed as per mg of protein and the tissue protein was estimated according
127 to the method of Lowry *et al.*, [13], using bovine serum albumin (BSA) as a standard.

128

129 2.9. *Statistical Analysis*

130 Results are expressed as mean \pm S.E.M. The levels of homogeneity among the groups
131 were assessed using One-way Analysis of Variance (ANOVA) followed by Turkey's test. All
132 analyses were done using Graph Pad Prism Software Version 5.00 and p values < 0.05 were
133 considered statistically significant.

134

135 **3. Results**

136 3.1. *Haematological Parameters*

137 The effects of codeine administration on haematological parameter were depicted in
138 Table 1. No significant changes in the parameters of HGB, HCT, RDW-CV, MPV, and
139 PDW were found when compared with control animals. However, administration of codeine
140 significantly lower ($p < 0.05$) white blood cell (WBC) count, red blood cell (RBC) count, and
141 platelet (PLT), while the value of mean corpuscular volume (MCV) and Mean Corpuscular
142 Haemoglobin (MCH) were increased when compared with control animals.

143

144

145

146

147

148

149

150

151

152

153

154

155 **Table 1:** Effect of codeine administration on haematological parameters of rats.
 156

Parameters	Control	Normal codeine	High codeine	Extreme codeine
WBC (X10 ⁹ /L)	8.30±0.35	4.18±0.22 **	4.94±0.74 **	4.56±0.34 **
HGB (g/dl)	10.58±0.39	9.88±0.08	10.66±0.64	10.67±0.13
RBC (x10 ¹² /L)	6.92±0.31	5.59±0.05 **	5.51±0.33 **	5.47±0.11 **
HCT (%)	31.64±0.97	29.00±0.32	32.00±1.58	32.00±0.32
MCV (fl)	55.50±0.87	56.48±0.54	67.70±1.15 **	67.70±1.15 **
MCH (pg)	15.28±0.31	17.60±0.19	19.30±0.28 **	19.42±0.22 **
MCHC (g/L)	275.64±1.93	313.00±2.21	286.60±2.6	290.80±2.46
RDW-CV (%)	17.22±0.31	16.30±0.25	17.84±0.38	17.32±0.16
RDW-SD (fl)	31.82±0.15	31.60±0.43	39.18±1.01	37.42±0.47
PLT (X10 ⁹ /L)	583.00±1.26	592.86±18.11	544.67±14.10	405.50±6.30 **
MPV (fl)	7.00±0.06	6.80±0.11	6.88±0.10	7.16±0.10
PDW	16.08±0.32	16.14±0.19	15.96±0.08	15.98±0.13
PTC (%)	0.39±0.00	0.40±0.02	0.33±0.01	0.33±0.04

157

158 Each value represents the mean of five rats. ** = significantly different from control (p <
 159 0.05).

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174 3.2. *Effect of Codeine Administration on Blood Biochemical Parameters*

175 Administration of codeine at normal, high and extreme doses significantly increased the
 176 activity of ALP by 75.39%, 149.36% and 122.65% respectively and AST activity by 31.82%,
 177 83.41% and 145.47% respectively when compared with the normal rats. The plasma
 178 concentration of creatinine and Urea were also significantly increased by all the three doses of
 179 codeine while total proteins level was decreased by administration of normal, high and
 180 extreme doses of codeine by 30.35%, 48.02% and 38.84% respectively when compared with
 181 the normal rats (Table 2).

182

183 **Table 2:** Effect of codeine administration on blood biochemical parameters

PARAMETERS	Control	Normal codeine	High codeine	Extreme codeine
ALP (IU/L)	100.74 ± 7.86	176.69 ± 11.57 **	251.21 ± 12.52 **	224.30 ± 15.76 **
AST (IU/L)	44.25 ± 1.15	58.33 ± 2.42 **	81.16 ± 4.45 **	108.62 ± 3.56 **
Creatinine (mg/dL)	0.83 ± 0.08	1.61 ± 0.25 **	2.44 ± 0.21 **	2.19 ± 0.32 **
Urea (mg/dL)	23.79 ± 1.64	46.46 ± 3.94 **	41.60 ± 3.51 **	33.39 ± 2.91 **
Total protein (g/dL)	8.60 ± 0.73	5.99 ± 0.36 **	4.47 ± 0.50 **	5.26 ± 0.47 **

184

185 Each value represents the mean of five rats. ** = significantly different from control (p <
 186 0.05).

187

188

189

190


191

192

193

194 3.3.Effect of Codeine Administration on TBARS Levels

195 Hepatic TBARS levels of rats treated with normal, high and extreme doses of codeine were
196 dose-dependently significantly increased by 58.26%, 131.42% and 234.74% respectively
197 when compared with the normal rats. Similarly, administration of codeine at normal, high and
198 extreme doses significantly increases renal TBARS levels by 57.59%, 114.14% and 157.23%
199 respectively when compared with the control rats (Figure 1).



200 **Figure 1.** Effect of codeine administration on hepatic and renal TBARS level of rats. Values
201 are mean \pm SEM (n=5). ** = significantly different from control (p < 0.05).
202
203

204

205

206


207

208

209 3.4. Effect of Codeine Administration on SOD Activity

210 Administration of codeine at normal, high and extreme doses significantly reduced
211 hepatic SOD levels by 39.06%, 61.74% and 57.29% respectively and reduced renal SOD
212 levels by 37.70%, 50.27% and 62.04% respectively when compared with normal rats (Figure
213 2).

214



215

216 **Figure 2.** Effect of codeine administration on hepatic and renal SOD activity of rats. Values
217 are mean \pm SEM (n=5). ** = significantly different from control ($p < 0.05$).

218

219

220


221

222

223

224 3.5. *Effect of Codeine Administration on Catalase Activity*

225 Administration of codeine at normal, high and extreme doses significantly reduced hepatic
226 catalase levels by 28.93%, 40.89% and 53.33% respectively and reduced renal catalase levels
227 by 45.92%, 61.73% and 40.30% respectively when compared with normal rats (Figure 3).



228

229 **Figure 3.** Effect of codeine administration on hepatic and renal catalase activity of
230 rats. Values are mean \pm SEM (n=5). ** = significantly different from control ($p < 0.05$).

231

232

233

234

235

236


237

238

239 3.6. *Effect of Codeine Administration on GSH Activity*

240 Hepatic GSH levels of rats treated with normal, high and extreme doses of codeine were
241 significantly reduced by 37.04%, 65.21% and 63.58% respectively when compared with the
242 normal rats. Similarly, administration of codeine at normal, high and extreme doses
243 significantly reduced renal GSH levels by 33.06%, 49.73% and 66.71% respectively when
244 compared with the control rats (Figure 4).

245



246

247 **Figure 4.** Effect of codeine administration on hepatic and renal GSH activity of rats. Values
248 are mean \pm SEM (n=5). ** = significantly different from control (p < 0.05).

249

250

251

252

253 4. Discussion

254 Codeine (Opioid) is an analgesic mainly used as an antitussive drug and to manage mild to
255 moderate pain [14,15]. It is, however, a drug of abuse because of its stimulatory effect
256 on CNS among some adults [16]. Toxic effects of codeine use have been reported, although
257 little is known about codeine toxicity mechanisms [2,17]. In this study, the toxic effects of
258 codeine were examined in animal models. Codeine was studied as a drug and not as an analgesic
259 because alarming misuse of codeine recently made Nigeria Government ban production and
260 importation of cough syrup that has codeine as an ingredient [8]. **Therefore, this study**
261 **evaluated the toxicity of codeine on systemic body organs because of people use of codeine**
262 **without doctor prescriptions.**

263 Free radicals and reactive oxygen species are generated by chemicals and pollutants such
264 as factory waste, toxic gases and they are known to disrupt biochemical and haematological
265 parameters in organisms [18]. Disruption of haematological parameters could provide
266 valuable information and insight into the diagnosis of various diseases and pathological
267 conditions. The deviation from normal haematological parameters levels represents the
268 presence of toxicity or disease conditions [19]. The decrease in red blood cell count (RBC)
269 level could be a result of an imbalance between its production and loss [20]. In this study,
270 codeine administration caused a significant reduction in red blood cell counts (RBC). The
271 observed decrease in the number of RBCs suggest that codeine administration resulted in
272 blood loss due to serious gastrointestinal tract bleeding, red blood cell haemolysis and poor
273 iron absorption in the intestine.

274 Codeine administration also resulted in a reduction of WBC of experimental animals in
275 this study. White blood cells fight infections, defend the body against foreign
276 organisms' invasion and produce antibodies in immune response [21]. Animals with low

277 WBC are at high risk of disease infection, while high WBC results in high resistance to
278 diseases [21]. Thereduction of WBC by codeine observed in this study agrees with pervious
279 study which revealed that abuse or long-term use of opium supresses the immune system and
280 individuals are more susceptible to infectious disease [22].

281 Blood platelets are involved in blood clotting and its low level will prolongthe process of
282 clot-formation resulting in excessive blood loss during injury. Although, there was no
283 significant variation in platelet concentration of rats administered with normal and high doses
284 of codeine in this study, however, the extreme dosage of codeine significant reduce platelet
285 concentration. A decreased number of platelet (thrombocytopenia) by codeine in this study is
286 in supports of pervious work which observed that morphine administration induced
287 thrombocytopenia [23]. Codeine administration also resulted in increased in the levels of
288 mean corpuscular haemoglobin (MCH) and mean corpuscular volume (MCV).We strongly
289 believe that disruption in haematological parameters observed in this study may be due to
290 increased population of unquenched free radicals caused by codeine administration.The
291 changes observed in other haematological parameters such as HGB, HCT, RDW%, RDW,
292 MCHC, MPV,PCT, PDW in this study were largely found to be non-significant, an
293 observation that may be different if codeine administration period was much longer than 28
294 days used in this study.

295 In this study, many biochemical parameters on liver and kidney functionswere determined
296 in plasma samples to assess damage to metabolizing organs. The increased in the activities of
297 ALT, aspartate aminotransferase (AST), ALP and lactate dehydrogenase (LDH) have been
298 reported in previous studies following exposure to opioids, including morphine and tramadol
299 [24-26]. Administration of codeine in this study significantly increased ALP and AST
300 activities which are in conformity with previous research that revealed that AST. ALP and
301 ALT activities in plasma increased significantly in an addicted patient of opioid[27].The liver

302 is anorgan that detoxified toxic elements and chemical drugs in the body,the **increase**in the
303 activities AST and ALP in plasma in this study are indicative of liver damage[28]. The
304 increased secretion of these liver enzymes may be accompanied by acute cell necrosis,
305 therefore, the increased plasma level of these enzymes in rats treated with codeine could be
306 due to necrosis or damage to liver cell membrane which leak the enzymes into the blood
307 circulation[29].

308 The level of plasma creatinine is used to determined glomerular filtration rate and serves
309 as renal function assessment[30]. Codeine administration significantly increased plasma
310 creatinine level of rats in this study and this can be taken as evidence of renal damage
311 because the high level of creatinine in the blood implies a loss of kidney function in ensuring
312 creatinine excretion. Similarly, administration of codeine in this study increased blood urea
313 concentration. Urea is a nitrogenous waste and product of protein and amino acid
314 metabolism, it is eliminated from the body through urinary excretion. It is an important
315 clinical parameter because it can be used to determine the nephrotoxic profile of xenobiotics.
316 The increased in blood urea concentration observed in this study following codeine
317 administration agrees with previous research [31]and it is an indication of renal toxicity
318 which might have instigated decrease in glomerular filtration rate leading to the build-up of
319 creatinine and urea in the blood.

320 There was a decrease in plasma total protein in rats treated with codeine in this study this
321 is in support of previous research finding which showed **decrease** in plasma total protein
322 levels in opium dependent participants when compared to the control group[32]. The clinical
323 diagnosis has shown that a decrease in plasma concentrations of protein characterized by
324 significant increases in the urinary excretion of protein and albumin are indicators of renal
325 dysfunction[33]. Therefore, the decrease in plasma total protein observed in this study can be
326 taken as an indication of kidney damage.

327 Administration of codeine resulted in increased levels of MDA the last metabolite of lipid
328 peroxidation chain, and inhibition of the antioxidant enzymes, superoxide dismutase (SOD),
329 catalase (CAT) and reduced glutathione (GSH) in liver and kidney of rats. Elevated levels of
330 MDA have been reported to be an indication of an increase in free radical generation and it is
331 considered a useful measure of oxidative stress status [34]. SOD, CAT and GSH are
332 important antioxidant enzymes which played a pivotal role in scavenging of oxidative free
333 radicals [35]. The inhibition of these antioxidant enzymes observed in this study could be
334 linked to exhaustion of these enzymes as a result of oxidative stress caused by codeine
335 administration.

336 The toxic effect of codeine administration leads to a large population of unquenched free
337 radicals leading to the state of oxidative stress. Oxidative stress form when there is an
338 imbalance between free radical generating and scavenging systems has been implicated in the
339 pathogenesis of a wide range of disorders, including neurodegenerative disorders,
340 cardiovascular diseases, cancer, and ageing [36].

341

342 **Conclusion**

343 Our results evidence that codeine administration may cause haematotoxicity, hepatotoxicity
344 and nephrotoxicity and as such, its use should be limited to prescription only. Our findings
345 underlined the need to avoid indiscriminately and prolong use of codeine, since prolonged
346 daily use of the drug either at a therapeutic dose or the extreme dose may lead to damage
347 accumulation.

348 **Ethical Approval:**

349 As per international standard or university standard ethical approval has been collected and
350 preserved by the authors.

351 **Conflict of Interests**

352 Authors have declared that no competing interests exist.

353 **Article type**

354 Original research paper

355

356

REFERENCES

- 357 1. Frost J,Løkken TN,Helland A,Nordrum IS,Slordal L. Post-mortem levels and tissue
358 distribution of codeine, codeine-6-glucuronide, norcodeine, morphine and morphine
359 glucuronides in a series of codeine-related deaths. *Forensic Sci. Int.*2016;262:128–
360 137.
361
- 362 2. Frost J,Helland A,Nordrum IS,Slordal L. Investigation of morphine and morphine
363 glucuronide levels a cytochrome P450 isoenzyme 2D6 genotype in codeine-related
364 deaths, *Forensic Sci. Int.* 2012;220:6–11.
365
- 366 3. Jaffe H, Martin WR. Opioid analgesics and antagonists. *The Pharmacological Basis*
367 *of Therapeutics* (A. G. Gilman, L. S. Goodman, and A. Gilman, Eds.). 6th Ed.,
368 Macmillian Co., New York. 1980;494-534.
369
- 370 4. Poulsen L,Brosen K, Arendt-Nielsen L, Gram LF,Elbaek K,Sindrup SH. Codeine and
371 morphine in extensive and poor metabolizers of sparteine: pharmacokinetics,
372 analgesic effect and side effects. *Eur. J. Clin. Pharmacol.*1996;51:289–295.
373
- 374 5. Sindrup SH, Arendt-Nielsen L,Brosen K, Bjerring P, Angelo HR, Eriksen B, Gram
375 LF. The effect of quinidine on the analgesic effect of codeine. *Eur. J. Clin. Pharmacol.*
376 1992;42:587–591.
377
- 378 6. Baselt RC. *Disposition of Toxic Drugs and Chemicals in Man*, 8th ed., Biomedical
379 Publications, Foster City, CA, 2008.
380
- 381 7. DAWN, Drug Abuse Warning Network 2011: National estimates of drug-related
382 emergency department visits, 2013.
383
- 384 8. O'Grady S.Nigeria bans codeine cough syrup to stop an addiction epidemic. But
385 something worse could take its place. *The Washington Post* May 4th 2018. Assessed:
386 28/01/2019 <https://www.washingtonpost.com/news/worldviews/wp/2018/05/04/>
387
- 388 9. Kakkar P, Das B, Viswanathan PN. A modified spectrophotometric assay of
389 superoxide dismutase, *Ind. J. Biochem. Biophys.*1984;21:130–132.

- 390
391 10. Aebi H. Catalase in vitro. *Methods Enzymol* 1974;105:121–126.
392
393 11. Jollow DJ, Mitchell JR, Zampaglione N, Gillete JR. Bromobenzene induced liver
394 necrosis: protective role of glutathione and evidence for 3,4 bromobenzeneoxide as
395 the hepatotoxic intermediate. *Pharmacology* 1974;11:151–169.
396
397 12. Draper HH, Hadley M. Malondialdehyde determination as index of lipid peroxidation.
398 *Methods Enzymol* 1990;186:421–431.
399
400 13. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin
401 phenol reagent. *J. Biol. Chem.* 1951;193:265– 275.
402
403 14. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J. Codeine
404 intoxication associated with ultra rapid CYP2D6 metabolism. *N. Engl. J. Med.*
405 2004;351:2827–2831.
406
407 15. Barnhart ER. Physicians' Desk Reference, Medical Economics Company, Oradell,
408 NJ. 40th ed. 1986.
409
410 16. Fraser HF. Patterns of abuse of narcotics: An historical overview. In *Drug abuse-*
411 *Proceedings of the International Conference* Lea &Febiger, Philadelphia (C. J. D.
412 Zarafonotis, Ed.), 1972;141-151.
413
414 17. Schulz M, Schmoldt A. Therapeutic and toxic blood concentrations of more than 800
415 drugs and other xenobiotics. *Pharmazie* 2003;58(7):447–474.
416
417 18. Celik I, Suzek H. The hematological effects of methyl parathion in rats. *J. Hazard.*
418 *Mater.* 2008;153:1117–1121.
419
420 19. Oyedemi SO, Bradley G, Afolayan AJ. Toxicological effects of the aqueous stem bark
421 extract of *Strychnos neriifolia* Gilg in Wistar rats. *J. Nat. Pharm.* 2010;1: 33–39.
422
423 20. Alabi QK, Akomolafe RO, Olukiran OS, Nafiu AO, Omole JG, Adefisayo AM, et al.
424 Assessment of haematological and biochemical effects of Kolaviron in Male Wistar
425 Rats. *Br J Pharm Res.* 2017;16(3):1–14.
426
427 21. Soetan KO, Akinrinde AS, Ajibade TO. Preliminary studies on the haematological
428 parameters of cockerels fed raw and processed guinea corn (*Sorghum bicolor*).
429 *Proceedings of 38th Annual Conference of Nigerian Society for Animal Production.*
430 2013;49-52.
431
432 22. Roy S, Wang J, Kelschenbach J, Koodie L, Martha J. Modulation of immune function
433 by morphine implications for susceptibility to infection. *Neuroimmune pharmacol.*
434 2006; 1, 77-89.
435
436 23. Cimo PL, Hammond JJ, Moake JL. Morphine-induced immune thrombocytopenia.
437 *Arch Intern Med* 1982;142(4):832-834.
438

- 439 24. Ali OK, Ahmed A-JS, Mawlood A-G. Effects of tramadol on histopathological and
440 biochemical parameters in male rabbits. *Am. J. Biol. Life Sci.* 2015;3:85–90.
441
- 442 25. Hafez E, Issa S, Rahman SA. Parenchymatous toxicity of tramadol: a
443 histopathological and biochemical study. *J. Alcohol Drug Depend.* 2015; 3.
444
- 445 26. Salahshoor MR, Khashiadeh M, Roshankhah S, Kakabaraei S, Jalili C. Protective effect
446 of crocin on liver toxicity induced by morphine. *Res. Pharm. Sci.* 2016;11: 120–129.
447
- 448 27. Sajad M, Chawla R, Zargan J, Umar S, Sadaqat M, Khan HA. Cytokinetics of adult
449 rat SVZ after EAE. *Brain Research.* 2011;1371:140-149.
450
- 451 28. Salashoor MR, Roshankhan S, Hosseni P, Jalili C. Genistein Improves Liver damage
452 in Male Mice Exposed to Morphine. *Chinese Medical Journal (Engl).*
453 2018;131(13):1598-1604.
454
- 455 29. Drotman RB, Lawhorn GT. Serum enzymes as indicators of chemically induced liver
456 damage. *Drug and Chemical Toxicology.* 1978;1(2):163-71
457
- 458 30. Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function:
459 new insights into old concepts. *Clin. Chem.* 1992;38(10):1933-53.
460
- 461 31. Hatem SM, Saussez G, Faille MD, Prist V, Zhang X, Dispa D, Bleyenheuft Y.
462 Rehabilitation of Motor Function after stroke: A Multiple Systematic Review Focused
463 on Techniques to stimulate upper extremity recovery. *Frontiers in Human*
464 *Neuroscience.* 2016;10:442.
465
- 466 32. Afarinesh MR, Haghpanah T, Divsalar K, Dehyadegary E, Shaaikh-Aleslami A,
467 Mahmoodi M. Changes in serum biochemical factors associated with opium addiction
468 after addiction desertion. *Addiction and Health.* 2014;6:138-145.
469
- 470 33. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme
471 inhibitors on mortality and morbidity in patients with heart failure. Collaborative
472 Group on ACE Inhibitor trials. *JAMA.* 1995;273(18):1450-1456
473
- 474 34. Pan HZ, Zhang H, Chang D, Li H, Sui H. The change of oxidative stress products in
475 diabetes mellitus and diabetic retinopathy, *Br. J. Ophthalmol.* 2008;92(4):548–551.
476
- 477 35. Kruidenier L, Kuiper I, Van Duijn W, Mieremet-Ooms MA, van Hogezaand
478 RA, Lamers CB, et al. Imbalanced secondary mucosal antioxidant response in
479 inflammatory bowel disease. *J Pathol.* 2003;201:17–27.
480
- 481 36. Halliwell B, Gutteridge JMC. Oxidative stress: Adaptation, damage, repair and death.
482 In: Halliwell B, Gutteridge JMC, Eds. *Free Radicals in Biology and Medicine*, 3rd
483 Edition, Oxford University Press, Oxford. 1999, 246-350.

484

485

486

487

488

489

490

491

UNDER PEER REVIEW